Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

Open access
Alatab, Sudabeh, Sepanlou, Sadaf G, Ikuta, Kevin, Vahedi, Homayoon, Bisignano, Catherine, Safiri, Saeid, Sadeghi, Anahita, Nixon, Molly R, Abdoli, Amir, Abolhassani, Hassan, Alipour, Vahid, Almadi, Majid A H, Almasi-Hashiani, Amir, Anushiravani, Amir, Arabloo, Jalal, Atique, Suleman, Awasthi, Ashish, Badawi, Alaa, Baig, Atif A A, Bhala, Neeraj, Bijani, Ali, Biondi, Antonio, Borzì, Antonio M, Burke, Kristin E, Carvalho, Félix, Daryani, Ahmad, Dubey, Manisha, Eftekhari, Aziz, Fernandes, Eduarda, Fernandes, João C, Fischer, Florian, Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hasanzadeh, Amir, Hashemian, Maryam, Hay, Simon I, Hoang, Chi L, Househ, Mowafa, Ilesanmi, Olayinka S, Jafari Balalami, Nader, James, Spencer L, Kengne, Andre P, Malekzadeh, Masoud M, Merat, Shahin, Meretoja, Tuomo J, Mestrovic, Tomislav, Mirrakhimov, Erkin M, Mirzaei, Hamid, Mohammad, Karzan A, Mokdad, Ali H, Monasta, Lorenzo, Negoi, Ionut, Nguyen, Trang H, Nguyen, Cuong T, Pourshams, Akram, Poustchi, Hossein, Rabiee, Mohammad, Rabiee, Navid, Ramezanzadeh, Kiana, Rawaf, David L, Rawaf, Salman, Rezaei, Nima, Robinson, Stephen R, Ronfani, Luca, Saxena, Sonia, Sepehrimanesh, Masood, Shaikh, Masood A, Sharafi, Zeinab, Sharif, Mehdi, Siabani, Soraya, Sima, Ali Reza, Singh, Jasvinder A, Soheili, Amin, Sotoudehmanesh, Rasoul, Suleria, Hafiz Ansar Rasul, Tesfay, Berhe E, Tran, Bach, Tsoi, Derrick, Vacante, Marco, Wondmieneh, Adam B, Zarghi, Afshin, Zhang, Zhi-Jiang, Dirac, Mae, Malekzadeh, Reza, Naghavi, Mohsen·2020·The Lancet Gastroenterology & Hepatology

Abstract

BACKGROUND: The burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and trends of disease in different countries and regions. Understanding these geographical differences is crucial for formulating effective strategies for preventing and treating IBD. We report the prevalence, mortality, and overall burden of IBD in 195 countries and territories between 1990 and 2017, based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. METHODS: We modelled mortality due to IBD using a standard Cause of Death Ensemble model including data mainly from vital registrations. To estimate the non-fatal burden, we used data presented in primary studies, hospital discharges, and claims data, and used DisMod-MR 2.1, a Bayesian meta-regression tool, to ensure consistency between measures. Mortality, prevalence, years of life lost (YLLs) due to premature death, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were estimated. All of the estimates were reported as numbers and rates per 100 000 population, with 95% uncertainty intervals (UI). FINDINGS: In 2017, there were 6·8 million (95% UI 6·4-7·3) cases of IBD globally. The age-standardised prevalence rate increased from 79·5 (75·9-83·5) per 100 000 population in 1990 to 84·3 (79·2-89·9) per 100 000 population in 2017. The age-standardised death rate decreased from 0·61 (0·55-0·69) per 100 000 population in 1990 to 0·51 (0·42-0·54) per 100 000 population in 2017. At the GBD regional level, the highest age-standardised prevalence rate in 2017 occurred in high-income North America (422·0 [398·7-446·1] per 100 000) and the lowest age-standardised prevalence rates were observed in the Caribbean (6·7 [6·3-7·2] per 100 000 population). High Socio-demographic Index (SDI) locations had the highest age-standardised prevalence rate, while low SDI regions had the lowest age-standardised prevalence rate. At the national level, the USA had the highest age-standardised prevalence rate (464·5 [438·6-490·9] per 100 000 population), followed by the UK (449·6 [420·6-481·6] per 100 000). Vanuatu had the highest age-standardised death rate in 2017 (1·8 [0·8-3·2] per 100 000 population) and Singapore had the lowest (0·08 [0·06-0·14] per 100 000 population). The total YLDs attributed to IBD almost doubled over the study period, from 0·56 million (0·39-0·77) in 1990 to 1·02 million (0·71-1·38) in 2017. The age-standardised rate of DALYs decreased from 26·5 (21·0-33·0) per 100 000 population in 1990 to 23·2 (19·1-27·8) per 100 000 population in 2017. INTERPRETATION: The prevalence of IBD increased substantially in many regions from 1990 to 2017, which might pose a substantial social and economic burden on governments and health systems in the coming years. Our findings can be useful for policy makers developing strategies to tackle IBD, including the education of specialised personnel to address the burden of this complex disease. FUNDING: Bill & Melinda Gates Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(19)30333-4

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Age-standardised prevalence rate (per 100 000 population) of IBD, both sexes, for 195 countries and territories, 2017. (B) Percentage change in age-standardised prevalence rate (per 100 000 population) of IBD, both sexes, for 195 countries and territories, 1990–2017 IBD=inflammatory bowel disease. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.
Figure 1 (A) Age-standardised prevalence rate (per 100 000 population) of IBD, both sexes, for 195 countries and territories, 2017. (B) Percentage change in age-standardised prevalence rate (per 100 000 population) of IBD, both sexes, for 195 countries and territories, 1990–2017 IBD=inflammatory bowel disease. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.CC BY · PubMed Central
Figure 2 Trends from 1990 to 2017 in number and age-standardised prevalence rates of IBD at the global level Error bars indicate the 95% uncertainty interval (UI) for prevalent cases. Shading indicates the 95% UI for the age-standardised prevelance rate. IBD=inflammatory bowel disease.
Figure 2 Trends from 1990 to 2017 in number and age-standardised prevalence rates of IBD at the global level Error bars indicate the 95% uncertainty interval (UI) for prevalent cases. Shading indicates the 95% UI for the age-standardised prevelance rate. IBD=inflammatory bowel disease.CC BY · PubMed Central
Figure 3 Age patterns by sex in 2017 of the total number of prevalent cases and age-specific prevalence rate of IBD at the global level IBD=inflammatory bowel disease.
Figure 3 Age patterns by sex in 2017 of the total number of prevalent cases and age-specific prevalence rate of IBD at the global level IBD=inflammatory bowel disease.CC BY · PubMed Central
Figure 4 Trends from 1990 to 2017 in number and age-standardised death rates of IBD at the global level Error bars indicate the 95% uncertainty interval (UI) for number of deaths. Shading indicates the 95% UI for the age-standardised death rate. IBD=inflammatory bowel disease.
Figure 4 Trends from 1990 to 2017 in number and age-standardised death rates of IBD at the global level Error bars indicate the 95% uncertainty interval (UI) for number of deaths. Shading indicates the 95% UI for the age-standardised death rate. IBD=inflammatory bowel disease.CC BY · PubMed Central
Figure 5 Global counts and age-specific rates of YLLs and YLDs due to IBD across age groups, 2017 Error bars indicate the 95% uncertainty interval (UI) for YLLs and YLDs. Shading indicates the 95% UI for the rates. YLLs=years of life lost. YLDs=years of life lived with disability. IBD=inflammatory bowel disease.
Figure 5 Global counts and age-specific rates of YLLs and YLDs due to IBD across age groups, 2017 Error bars indicate the 95% uncertainty interval (UI) for YLLs and YLDs. Shading indicates the 95% UI for the rates. YLLs=years of life lost. YLDs=years of life lived with disability. IBD=inflammatory bowel disease.CC BY · PubMed Central
Figure 6 Trends from 1990 to 2017 in age-standardised death rate of IBD in seven GBD super-regions IBD=inflammatory bowel disease. GBD=Global Burden of Disease, Injuries, and Risk Factors Study.
Figure 6 Trends from 1990 to 2017 in age-standardised death rate of IBD in seven GBD super-regions IBD=inflammatory bowel disease. GBD=Global Burden of Disease, Injuries, and Risk Factors Study.CC BY · PubMed Central
Figure 7 Age-standardised prevalence rate of IBD globally and for 21 GBD regions by SDI, 1990–2017 For each region, points from left to right depict estimates from each year from 1990 to 2017. IBD=inflammatory bowel disease. GBD=Global Burden of Disease, Injuries, and Risk Factors Study.
Figure 7 Age-standardised prevalence rate of IBD globally and for 21 GBD regions by SDI, 1990–2017 For each region, points from left to right depict estimates from each year from 1990 to 2017. IBD=inflammatory bowel disease. GBD=Global Burden of Disease, Injuries, and Risk Factors Study.CC BY · PubMed Central
Figure 8 Age-standardised death rate of IBD globally and for 21 GBD regions by SDI, 1990–2017 The expected age-standardised death rate in 2017 based solely on SDI is represented by the black line. For each region, points from left to right depict estimates from each year from 1990 to 2017. IBD=inflammatory bowel disease. SDI=Socio-demographic Index.
Figure 8 Age-standardised death rate of IBD globally and for 21 GBD regions by SDI, 1990–2017 The expected age-standardised death rate in 2017 based solely on SDI is represented by the black line. For each region, points from left to right depict estimates from each year from 1990 to 2017. IBD=inflammatory bowel disease. SDI=Socio-demographic Index.CC BY · PubMed Central
Figure 9 Trends from 1990 to 2017 in age-standardised prevalence rates of IBD by SDI quintile IBD=inflammatory bowel disease. SDI=Socio-demographic Index.
Figure 9 Trends from 1990 to 2017 in age-standardised prevalence rates of IBD by SDI quintile IBD=inflammatory bowel disease. SDI=Socio-demographic Index.CC BY · PubMed Central
Figure 10 Age-standardised DALYs rates from IBD by SDI for 195 countries and territories in 2017 The black line represents the expected age-standardised DALY rate of IBD based solely on SDI. DALY=disability-adjusted life-year. IBD=inflammatory bowel disease. SDI=Socio-demographic Index.
Figure 10 Age-standardised DALYs rates from IBD by SDI for 195 countries and territories in 2017 The black line represents the expected age-standardised DALY rate of IBD based solely on SDI. DALY=disability-adjusted life-year. IBD=inflammatory bowel disease. SDI=Socio-demographic Index.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 2,313

Metadata

Authors
Alatab, S., Sepanlou, S. G., Ikuta, K., Vahedi, H., Bisignano, C., Safiri, S., Sadeghi, A., Nixon, M. R., Abdoli, A., Abolhassani, H., Alipour, V., Almadi, M. A. H., Almasi-Hashiani, A., Anushiravani, A., Arabloo, J., Atique, S., Awasthi, A., Badawi, A., Baig, A. A. A., Bhala, N., Bijani, A., Biondi, A., Borzì, A. M., Burke, K. E., Carvalho, F., Daryani, A., Dubey, M., Eftekhari, A., Fernandes, E., Fernandes, J. C., Fischer, F., Haj-Mirzaian, A., Haj-Mirzaian, A., Hasanzadeh, A., Hashemian, M., Hay, S. I., Hoang, C. L., Househ, M., Ilesanmi, O. S., Jafari Balalami, N., James, S. L., Kengne, A. P., Malekzadeh, M. M., Merat, S., Meretoja, T. J., Mestrovic, T., Mirrakhimov, E. M., Mirzaei, H., Mohammad, K. A., Mokdad, A. H., Monasta, L., Negoi, I., Nguyen, T. H., Nguyen, C. T., Pourshams, A., Poustchi, H., Rabiee, M., Rabiee, N., Ramezanzadeh, K., Rawaf, D. L., Rawaf, S., Rezaei, N., Robinson, S. R., Ronfani, L., Saxena, S., Sepehrimanesh, M., Shaikh, M. A., Sharafi, Z., Sharif, M., Siabani, S., Sima, A. R., Singh, J. A., Soheili, A., Sotoudehmanesh, R., Suleria, H. A. R., Tesfay, B. E., Tran, B., Tsoi, D., Vacante, M., Wondmieneh, A. B., Zarghi, A., Zhang, Z.-J., Dirac, M., Malekzadeh, R., & Naghavi, M.
Affiliations
University of Washington (US)
Corresponding author
Naghavi, Mohsen
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2020-01
Volume
5
Issue
1
Pages
17-30
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W2981768636
Cited by
2,313
References
33
Citations by year
2026: 232 · 2025: 373 · 2024: 445 · 2023: 460 · 2022: 374 · 2021: 300 · 2020: 123
FWCI
120.14
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Federal Open Science Repository of Canada / Le Dépôt fédéral de science ouverte du Canada (submittedVersion, cc-by)
  • RMIT Research Repository (RMIT University Library) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • UTS ePRESS (University of Technology Sydney) (submittedVersion, other-oa)
  • PUB – Publications at Bielefeld University (Bielefeld University) (submittedVersion, cc-by)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • Università di Catania
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute
  • Trường Đại học Nguyễn Tất Thành
  • Iran University of Medical Sciences
  • Applied Molecular Biosciences Unit
  • Public Health Institute
  • Johns Hopkins University
  • Urmia University of Medical Sciences
  • Babol University of Medical Sciences
  • University of Melbourne
  • Queen Elizabeth Hospital Birmingham Charity
  • Trường Đại học Y Hà Nội
  • Universität Bielefeld
  • Universidade do Porto
  • National Cancer Institute
  • Department of Radiology, Weill Cornell Medical College
  • Guilan University of Medical Sciences
  • College of Medicine, University of Florida
  • Islamic Azad University
  • Kashan University of Medical Sciences
  • University of Birmingham
  • UCLH Biomedical Research Centre
  • Department of Chemistry, University of York
  • Department of Biology, University of New Mexico
  • Trường Đại học Duy Tân
  • Amirkabir University of Technology
  • University of Ibadan
  • Utica College
  • King Saud University
  • McGill University
  • Public Health Agency of Canada
  • Kermanshah University of Medical Sciences
  • Helsingin ja Uudenmaan Sairaanhoitopiiri
  • Institute for Health Metrics and Evaluation
  • Mazandaran University of Medical Sciences
  • Hamad Bin Khalifa University
  • Jahrom University of Medical Sciences
  • Maragheh University of Medical Sciences
  • Sharif University of Technology
  • University of Louisiana at Lafayette
  • Zanjan University of Medical Sciences
  • Bill and Melinda Gates Foundation
  • Ministério da Ciência, Tecnologia e Ensino Superior (UID/MULTI/04378/2019, UID/Multi/50016/2019, UID/QUI/50006/2019)
  • Fuel Cell Technologies Program
  • Department of Science and Technology, Ministry of Science and Technology, India
  • University of Toronto
  • University of Washington
  • University of Cape Town
  • Tabriz University of Medical Sciences
  • University of Technology Sydney
  • Department of Medicine, Georgetown University
  • Shiraz University of Medical Sciences
  • Medical Research Council
  • Lorestan University of Medical Sciences
  • Division of Gastroenterology and Hepatology, School of Medicine, Indiana University
  • Addis Ababa University
  • Razi Herbal Medicines Research Center
  • School of Medicine
  • Shahid Beheshti University of Medical Sciences
  • College of Science and Engineering, University of Minnesota
  • Public Health England
  • School of Medicine and Public Health, University of Wisconsin-Madison
  • Salahaddin University-Erbil
  • University of Hail
  • Department of Psychology, Western Washington University
  • Babol Noshirvani University of Technology
  • University of Alabama
  • Wuhan University
  • Massachusetts General Hospital
  • Adigrat University
  • Universiti Sultan Zainal Abidin
Topics
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
Keywords
inflammatory bowel disease, Crohn's disease, ulcerative colitis, disease burden, prevalence, mortality, years of life lost, years lived with disability, disability-adjusted life years, global health burden, regional variation, temporal trends, causes of death, risk factors
MeSH terms
Global Burden of Disease, Adult, Aged, Aged, 80 and over, Bayes Theorem, Cause of Death, Female, Humans, Male, Morbidity, Retrospective Studies, Socioeconomic Factors, Global Health, Inflammatory Bowel Diseases, Prevalence, Survival Rate, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. https://app.cochat.ai/papers/10.1016/s2468-1253(19)30333-4
The paper
Alatab, S., Sepanlou, S. G., Ikuta, K., Vahedi, H., Bisignano, C., Safiri, S., Sadeghi, A., Nixon, M. R., Abdoli, A., Abolhassani, H., Alipour, V., Almadi, M. A. H., Almasi-Hashiani, A., Anushiravani, A., Arabloo, J., Atique, S., Awasthi, A., Badawi, A., Baig, A. A. A., . . . Naghavi, M. (2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(19)30333-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.